Novel radioligands for imaging sigma-1 receptor in brain using positron emission tomography (PET)

Yu Lan\textsuperscript{a, d}, Ping Bai\textsuperscript{a}, Zude Chen\textsuperscript{a}, Ramesh Neelamegam\textsuperscript{b}, Michael S. Placzek\textsuperscript{a}, Hao Wang\textsuperscript{a}, Stephanie A. Fiedler\textsuperscript{a}, Jing Yang\textsuperscript{a}, Gengyang Yuan\textsuperscript{b}, Xiying Qu\textsuperscript{b}, Hayden R. Schmidt\textsuperscript{c}, Jinchun Song\textsuperscript{d}, Marc D. Normandin\textsuperscript{b}, Chongzhao Ran\textsuperscript{a}, Changning Wang\textsuperscript{a, *}

\textsuperscript{a}Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
\textsuperscript{b}Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
\textsuperscript{c}Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02129, USA
\textsuperscript{d}Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan 430060, China

Received 6 April 2019; received in revised form 28 June 2019; accepted 4 July 2019

\textbf{KEY WORDS}
\sigma_1 R; PET; Brain imaging; 6-Hydroxypyridazinone; \textsuperscript{11}C-labeled radioligand

\textbf{Abstract} The \textit{sigma-1 receptor (}\sigma_1 \textit{R}) is a unique intracellular protein. \sigma_1 R plays a major role in various pathological conditions in the central nervous system (CNS), implicated in several neuropsychiatric disorders. Imaging of \sigma_1 R in the brain using positron emission tomography (PET) could serve as a noninvasively tool for enhancing the understanding of the disease’s pathophysiology. Moreover, \sigma_1 R PET tracers can be used for target validation and quantification in diagnosis. Herein, we describe the radiosynthesis, \textit{in vivo} PET/CT imaging of novel \sigma_1 R \textsuperscript{11}C-labeled radioligands based on 6-hydroxypyridazinone, \textsuperscript{[11]C}HCC0923 and \textsuperscript{[11]C}HCC0929. Two radioligands have high affinities to \sigma_1 R, with good selectivity. In mice PET/CT imaging, both radioligands showed appropriate kinetics and distributions. Additionally, the specific interactions of two radioligands were reduced by compounds \textsuperscript{13} and \textsuperscript{15} (self-blocking). Of

\textbf{Abbreviations}: 3D, three-dimensional; \sigma_1 R, sigma-1 receptor; \sigma_2 R, sigma-2 receptor; AF, ammonium formate; BBB, brain blood barrier; BP, binding potential; CNS, center nervous systems; CRPS, complex regional pain syndrome; DMF, dimethyl formamide; DMSO, dimethylsulfoxide; ER, endoplasmic reticulum; LCP, lipidic cubic phase; MAM, mitochondria-associated ER membrane; PCP, phencyclidine; PET, positron emission tomography; TFA, tri-fluoroacetic acid.

*Corresponding author. Tel./fax: +1 617 724 9390.
E-mail address: cwang15@mgh.harvard.edu (Changning Wang).

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

https://doi.org/10.1016/j.apsb.2019.07.002
2211-3853 © 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the two, $^{[1]}$C$\text{HCC0929}$ was further investigated in positive ligands blocking studies, using classic $\sigma_1$R agonist SA 4503 and $\sigma_2$R antagonist PD 144418. Both $\sigma_1$R ligands could extensively decreased the uptake of $^{[1]}$C$\text{HCC0929}$ in mice brain. Besides, the biodistribution of major brain regions and organs of mice were determined in vivo. These studies demonstrated that two radioligands, especially $^{[1]}$C$\text{HCC0929}$, possessed ideal imaging properties and might be valuable tools for non-invasive quantification of $\sigma_1$R in brain.

© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

As an enigmatic intracellular protein, the history of sigma ($\sigma$) receptor was originally categorized as an opioid receptor subtype, and later confused with the phencyclidine (PCP) receptor due to the lack of selective ligands. Subsequent pharmacological studies and molecular biology have finally identified that the $\sigma$ receptor is a non-opioid and non-PCP protein, which was at least two known subtypes, classified as sigma-1 ($\sigma_1$) and sigma-2 ($\sigma_2$) receptor. These two subtypes are pharmacologically similar but genetically unrelated, with different body distribution, biological function and pharmacological profiles.

At present, sigma-1 receptor ($\sigma_1$R) is known as a unique protein that shares no sequence homology with opioids or any other human proteins but is highly conserved across mammalian species. $\sigma_1$R is a 23.5 kDa that is 223 amino acids in length. $\sigma_1$R is widely expressed in the central nervous system (CNS) and peripheral tissues and organs.

Mainly residing in the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) of cell, $\sigma_1$R has been reported to interacted with numerous neurotransmitter receptors and ion channels, involved in diverse basic biochemical processes and pathological conditions related to neurodegeneration, pain sensitization, psychiatric disorders, and drug addiction. $\sigma_1$R is also found overexpressed in many known human cancers in lung, breast, prostate, and glioma cells.

The first crystal structure of human $\sigma_1$R was recently solved using lipidic cubic phase (LCP) crystallography. The three-dimensional (3D) protein structure of human $\sigma_1$R receptor showed a membrane-bound trimeric assembly with one transmembrane region, modifying the previous hypothesis that the receptor had two transmembrane domains. Despite the fact that structural information has only recently become available, and no endogenous ligand has been established for the receptor, numerous small molecule ligands for $\sigma_1$R have been reported over the past few decades. Among these compounds, some have been developed as radiolabeled imaging tracers for positron emission tomography (PET) applications.

As a translational noninvasive imaging method, PET imaging of $\sigma_1$R is a promising modality to evaluate distribution and expression in inaccessible regions and tissues. Additionally, with the specificity and selectivity radioligands, examining $\sigma_1$R through PET could facilitate the investigation of in vivo role in pathology and progression of $\sigma_1$R in different diseases.

Several radiolabeled $\sigma_1$R ligands have been studied in PET imaging of human investigation, but only a few of them have been used clinically. $^{[1]}$C$\text{SA 4503}$ (1) is the first $\sigma_1$R radioligand in human studies. The ex vivo binding assays of SA 4503 was initially reported as nanomolar affinity of $\sigma_1$R ($K_i = 4.6 \text{ nmol/L}$) and highly selectivity to $\sigma_2$R ($\sigma_2/\sigma_1 = 103$). Later the selectivity to $\sigma_2$R was reinvestigated as 13.3—55.0. Besides, the low selectivity either to the enomapil binding protein (EBP) or to the vascular acetylcholine transporter (VACHT) limited its broad use in clinical studies. There are also fluorine-18-labeled $\sigma_1$R radioligands, including but not limited to $^{[18]}$F$\text{FMSA4503}$, $^{[18]}$F$\text{FPS}^{-}$, $^{[18]}$F$\text{SFE}^{23,24}$, and $^{[18]}$F$\text{FTC-146}$. Although most of them have been studied in human researches, $^{[18]}$F$\text{FTC-146}$ have completed early phase I trial of PET/MRI in healthy volunteers, and in complex regional pain syndrome (CRPS) and sciatica, still each of them have unmet requirements and needs further investigation for practical clinic translation.

In our previous work, we identified 6-hydroxytryptamidine class of compounds with high $\sigma_1$R affinity and high selectivity over $\sigma_2$R. Ex vivo tests suggested comp-54 (6) of 6-hydroxytryptamidine derivatives were reported as the most promising candidate of high binding affinity ($\sigma_1$R $K_i = 1.4 \text{ nmol/L}$) and apparent good selectivity ($\sigma_2/\sigma_1 = 1365.7$). The pharmacological test of in vivo evaluation in rodent showed it was a $\sigma_1$R antagonist and could possibly penetrate the blood–brain barrier (BBB), and get into the $\sigma_1$R-expressed region in mice brain, which exerted a highly potency of modified into $\sigma_1$R radioligand for brain PET imaging. Aiming to preserve this high affinity and selectivity, we devised a strategy to modify 6 in ways that would incorporate a carbon-11 radiolabel without greatly altering the original framework of 6-hydroxytryptamidine in the target molecules.

To the best of our knowledge, no similar compounds with 6-hydroxytryptamidine scaffold have been developed as $\sigma_1$R PET radiotracer. Since the core structure is distinct from existing PET radioligands for $\sigma_1$R imaging, it could expand the diversity of available probes and facilitate future advances in a $\sigma_1$R imaging. Here, we report the radiosynthesis of two novel carbon-11-labeled $\sigma_1$R radioligands, $^{[1]}$C$\text{HCC0923}$ and $^{[1]}$C$\text{HCC0929}$, and demonstrate the in vivo pharmacokinetic properties, biodistribution of brain regions and major organs through PET/CT imaging for $\sigma_1$R in the mice.

2. Results and discussion

2.1. Chemical synthesis

The chemical synthesis of the compounds 13—15 was illustrated in Scheme 1. The 6-hydroxytryptamidine derivatives were prepared following our previously reported work with minor changes.

Briefly, through a one-step cyclization reaction of substitute phenylhydrazine hydrochloride and maleic anhydride, the
intermediates 9 and 10 were prepared as white solid; Next, standard alkylation with 1,3-dibromopropane in acetone using potassium carbonate (K$_2$CO$_3$) was conducted to produce 11 and 12, and then reacted with the piperidine, tert-butyl piperazine-1-carboxylate or 1-methylpiperazine respectively in the presence of cesium carbonate (Cs$_2$CO$_3$) in acetonitrile to afford the compound 13—15 in moderate yields.

2.2. Preparation of the precursors and radiosynthesis of $[^{11}C]$HCC0923 and $[^{11}C]$HCC0929

The preparation of the precursors P1 and P2 were using straightforward methods, as presented in Scheme 2. For precursor P1, the methoxy group in compound 13 was turned to hydroxy group by demethylation of BBr$_3$ in $-78\,\text{°C}$\cite{note}. For precursor P2, the tert-butyl ester in compound 14 was hydrolyzed in the presence of HCl solution in diethyl ether (2 mol/L) to form the designed precursor.

Two carbon-11-labeled radioligands were prepared through a standard methylation method, under the catalyzation of different bases, respectively. $[^{11}C]$HCC0923 was prepared through precursor P1 with $[^{11}C]$CH$_3$I. $[^{11}C]$CH$_3$I was produced from cyclotron and then trapped in a sealed vial with the precursor in DMF solution in the presence of sodium hydroxide (NaOH) followed by heating at $120\,\text{°C}$ for 3 min. The reaction was consequently quenched with water and purified by semipreparative HPLC. Including formulation, $[^{11}C]$HCC0923 was prepared in 35—40 min after the end of bombardment with adequate radiochemical yields (6%—15%, uncorrected for decay and based on trapped $[^{11}C]$CH$_3$I) and high radiochemical purity (>95%).

The procedure for synthesis of $[^{11}C]$HCC0929 was almost the same as $[^{11}C]$HCC0923, except using precursor P2 with K$_2$CO$_3$ as the base catalyst instead of NaOH. The entire preparation including formulation takes approximately 35—40 min, with the radiochemical yields of 3%—8% (uncorrected for decay and based on trapped $[^{11}C]$CH$_3$I) and radiochemical purity over 95%.

2.3. Ex vivo $\sigma_1$R binding affinity, selectivity and logD of compounds 13 and 15

An essential property of developing binding-based radiotracer is the binding potential (BP), which is usually represented as the ratio of receptor’s density ($B_{\text{max}}$) to binding affinity. A radiotracer which is suitable for quantitative comparisons with PET imaging has at least a value of BP over 5, especially in clinical investigation; in a non-research clinical setting, BP should typically be greater than 10$^{13}$. 

---

**Scheme 1** Synthesis of 6-hydroxypyridazinone derivatives. Reagents and conditions: (a) maleic anhydride, H$_2$O, conc. HCl, 100 °C, 8 h; (b) Br(CH$_2$)$_3$Br, K$_2$CO$_3$, acetone, 58 °C, 4 h; (c) Cs$_2$CO$_3$, acetonitrile, 62 °C, 2 h.
The $B_{\text{max}}$ of $\alpha_1$R in human brain was measured to be approximately 30–600 fmol/mg (3–60 nmol/L) $^{32,33}$. Thus, the radioligand with affinity of 0.6–12 nmol/L could be used for $\alpha_1$R imaging, and range of 0.3–6 nmol/L will be more suitable. The $\alpha_1$R binding affinities of 13 and 15 were 10.3 and 5.6 nmol/L, with the selectivities of 111.3- and 272.8-fold to $\alpha_2$R, respectively (Table 1,13,27). Compared to the most promising compound 6, both 13 and 15 showed a slight decrease of $\alpha_1$R binding affinity and selectivity, due to structure modifications necessary for radiolabeling; however, based on the criteria mentioned above, 13 and 15 still possessed suitable affinities for in vivo PET imaging of $\alpha_1$R.

Besides the binding affinity and selectivity to the target receptor, the logD is also another important parameter, especially for the radiotracer for brain imaging. The experimental logD PBS,pH7.4/C6SD of compounds 13 and 15 were measured to be 0.89±0.06 and 1.73±0.08, respectively.

2.4. Molecular docking studies of 6-hydroxypyridazinone derivatives

To predict the possible binding mode of the two radioligands, we performed molecular docking with Schrödinger Glide software (Schrödinger, LLC, New York, NY, USA) using the 2.5 Å resolution structure of the $\alpha_1$R bound to PD 144418, in a similar manner as reported previously $^{13,14,35}$.

Encouragingly, the top-ranked docked pose of PD 144418 in Fig. 2A (yellow) was nearly identical to that seen in the crystal structure (Fig. 2A, cyan), and the Glide score was comparable to

---

**Scheme 2** Synthesis of radiolabeling precursor P1 (16), P2 (17) and radiosynthesis of [11C]HCC0923 and [11C]HCC0929. Reagents and conditions: (a) BBr3, dichloromethane, –78 °C to room temperature, overnight; (b) NaOH, DMF, 120 °C, 3 min; (c) 2 mol/L HCl in diethyl ether, dichloromethane, room temperature, overnight; (d) K2CO3, DMF, 120 °C, 3 min.

---

**Table 1** Ex vivo binding affinities for $\alpha_1$R and $\alpha_2$R of PD 144418, compounds 6, 13 and 15.

| Compd.   | $\alpha_1$R $K_D$ or $K_i$ (nmol/L) | $\alpha_2$R $K_i$ (nmol/L) | Selectivity ($\alpha_2$R/$\alpha_1$R) |
|----------|---------------------------------|---------------------------|--------------------------------------|
| PD 144418 $^{13}$ | 4.3 ± 0.1 | 1377 ± 179 | |
| 6 $^{27}$ | 1.4 ± 0.1 | 1912 ± 210 | 1365.7 |
| 13 | 10.3 ± 1.1 | 1146 ± 116 | 111.3 |
| 15 | 5.6 ± 0.7 | 1528 ± 120 | 272.8 |

– Not applicable.

---

**Figure 2** Glide docking of compounds into the $\alpha_1$R (PDB 5HK1). (A) Pose of co-crystallized PD 144418 (pale cyan) and top-ranked pose from Glide docking (yellow). Best docked poses for (B) compound 6 (periwinkle), (C) compound 13 (cyan), (D) compound 15 (gold). In all panels, the receptor is shown in gray.
what has been reported previously for high-affinity \( \sigma_1 \)R ligands\(^{13,14,35}\).

The reference compound 6, along with 13 and 15, was docked in the same way. All three compounds adopted similar conformations in the ligand-binding site as PD 144418, with good Glide Scores (Table 2). Like all ligands co-crystallized with the receptor to date, the poses for compounds 6, 13, and 15 featured an electrostatic interaction between the positively charged nitrogen in the ligand and E172 (Table 2, Fig. 2B–D). Additionally, as reported for all currently co-crystallized \( \sigma_1 \)R antagonists\(^{8,14}\), the primary hydrophobic regions of these compounds were positioned near Y203, pointing towards the membrane, and the secondary hydrophobic regions were pointing towards the bottom of the ligand binding site past D126. These results suggest that these compounds likely bind the receptor similarly to other high-affinity \( \sigma_1 \)R ligands.

2.5. In vivo PET-CT imaging with \([11C]HCC0923 in mice\)\(^{16,37}\)

Following the encouraging data in ex vivo \( \sigma_1 \)R binding assays and molecular docking, two radioligands, \([11C]HCC0923 and [11C]HCC0929\), were a step forward to further in vivo investigation.

We firstly assessed \([11C]HCC0923 in vivo conducting dynamic PET imaging focused on mice brains. In PET-CT studies, \([11C]HCC0923 exerted high BBB penetration and fast uptake when administered by intravenous bolus injection (100–150 \( \mu \)Ci per animal), as shown in Fig. 3. Based on a whole-brain analysis, the concentration of \([11C]HCC0923 in the mice brain reached a maximum uptake of 6.48% ID/cc within the first few minutes after injection, and sustained binding over the scanning time (60 min).

To investigate the specificity of \([11C]HCC0929\), we performed PET imaging studies in mice with a 5-min pretreatment of compound 13 (unlabeled HCC0923) at different doses (1.25 and 12.5 mg/kg). Compared with the non-pretreat control (baseline, Fig. 3A), we found that \([11C]HCC0923 binding in mice brain was blocked in a dose-dependent manner with a stepwise reduction in the percent tracer uptake after administration of 13 (Fig. 3B and C). At 1.25 mg/kg, we found an approximate 38\% reduction in binding, estimated as the percent change in whole-brain radioactivity between peak uptake at 10 min and the lowest uptake at 60 min. Increasing the dose of 13 to 12.5 mg/kg resulted in a \( \sim 54\% \) reduction in \([11C]HCC0923 brain uptake, a dose-dependent response to self-blockade and \( \sim 45\% \) of uptake attributed to non-specific binding. We observed a similar blockade level at the last 10 min, indicating saturation at 1.25 mg/kg. This finding demonstrates a high specific binding of \([11C]HCC0923 for \( \sigma_1 \)R, with a dose-dependent response to self-blockade.

2.6. In vivo PET-CT imaging with \([11C]HCC0929 in mice\)\(^{40,37}\)

\([11C]HCC0929 was also studied in mice PET-CT imaging due to its better \( \sigma_1 \)R affinity. To test \([11C]HCC0929 as a radiotracer in vivo, we conducted PET imaging focused on the mice brains. Compared to \([11C]HCC0923, we determined that \([11C]HCC0929 exhibited more potent properties in PET imaging studies: higher BBB penetration and faster signal decrease over the 60-min scan when administered by intravenous bolus injection (100–150 \( \mu \)Ci per animal), as shown in Fig. 4.

Unlike the slow gradient of baseline curve of \([11C]HCC0923, the whole-brain analysis that exerted the concentration of \([11C]HCC0929 in the mice brain reached a maximum uptake of 7.66% ID/cc at \( \sim 5 \) min after injection with moderate wash-out rate during the scanning period (60 min), indicating a faster brain clearance kinetic property compared to \([11C]HCC0923. The specificity of \([11C]HCC0929 was investigated in mice PET imaging studies with a 5-min i.v. pretreatment of compound 15 (unlabeled HCC0929) at doses of 0.288 and 2.88 mg/kg.

We found that administration of 0.288 mg/kg unlabeled HCC0929 (15) blocked \([11C]HCC0929 binding in the mice brain by approximately 36\%, measured as the percent change in whole radioactivity between peak uptake at \( \sim 5 \) min and the lowest uptake at 60 min. Increasing the dose of 15 to 2.88 mg/kg resulted in a \( \sim 58\% \) reduction in \([11C]HCC0929 mice brain uptake (Fig. 4D), which represents a dose-dependent response to self-blockade and \( \sim 40\% \) of uptake attributed to non-specific binding.

The mice in vivo PET-CT studies demonstrated a high uptake and good mice brain clearance kinetic of \([11C]HCC0929 for \( \sigma_1 \)R imaging in brain, with a dose-dependent response to self-blockade.

2.7. Positive ligands blocking study of in vivo PET-CT imaging using \([11C]HCC0929 in mice\)

To further validate the selectivity of \( \sigma_1 \)R of the candidate radioligand \([11C]HCC0929, two highly \( \sigma_1 \)R selective ligands, SA 4503 (\( \sigma_1 \)R agonist) and PD 144418 (\( \sigma_1 \)R antagonist) were adopted for positive ligands blocking study\(^{36,37}\).

Through the in vivo PET-CT imaging in mice brain (Fig. 5), we found that administration of SA 4503 (2.75 mg/kg) or PD 144418 (2.99 mg/kg) could remarkably reduce the \([11C]HCC0929 binding in the mice brain by approximately 41\% and 67\%, respectively, measured as the percent change in whole radioactivity between peak uptake at \( \sim 5 \) min and the lowest uptake at 60 min. The different blocking effects of two positive ligands might due to their entirely opposite functional profiles. The shape of time–active curve of self-blocking was close to the curve of PD 144418, since the compound 15 acted as the same as antagonist, but the binding affinity to \( \sigma_1 \)R was a little higher than PD 144418.

2.8. In vivo biodistribution studies of \([11C]HCC0929 in mice\)

The biodistribution of radioligand \([11C]HCC0929 in mice was investigated by in vivo PET-CT imaging, and the data were acquired by using the FUSION module in PMOD (PMOD 4.003, PMOD Technologies Ltd., Zurich, Switzerland).

The analysis of detailed distribution of different brain regions of mice was obtained through the mouse (Ma-Benveniste-Mirione) VOI atlas\(^{38,39}\). Eight important functional regions of mice brain were selected: cortex, cerebellum, brain stem, thalamus,
Figure 3  Mice brain PET/CT images 25–60 min after intravenous administration (i.v.) of radioligand $[^{11}C]$HCC0923 and time–activity curve. (A) Baseline PET/CT image. (B) and (C) PET/CT image from blocking study, involving i.v. pretreatment with unlabeled HCC0923 (self-blocking, B: 1.25 mg/kg, C: 12.5 mg/kg) 5.0 min before radioligand injection. (D) Time–activity curve demonstrating uptake of radioligand for baseline and blocking studies (low & high dose).

Figure 4  Mice brain PET/CT images 25–60 min after intravenous administration (i.v.) of radioligand $[^{11}C]$HCC0929 and time–activity curve. (A) Baseline PET/CT image. (B) and (C) PET/CT image from blocking study, involving i.v. pretreatment with unlabeled HCC0929 (self-blocking, B: 0.288 mg/kg, C: 2.88 mg/kg) 5.0 min before radioligand injection. (D) Time–activity curve demonstrating uptake of radioligand for baseline and blocking studies (low & high dose).

Figure 5  Mice brain PET/CT images 25–60 min after intravenous administration (i.v.) of radioligand $[^{11}C]$HCC0929 and time–activity curve. (A) Baseline PET/CT image ($n=2$); PET/CT image from blocking study, involving i.v. pretreatment with positive compounds 5.0 min before radioligand injection: (B) unlabeled HCC0929 (self-blocking, 2.88 mg/kg); (C) SA 4503 ($\sigma_1$R agonist, 2.75 mg/kg); (D) PD 144418 ($\sigma_1$R agonist, 2.99 mg/kg); (E) Time–activity curve demonstrating uptake of radioligand for baseline and blocking studies (low & high dose).
hypothalamus, striatum, hippocampus and amygdala. The radio-
ligand [11C]HCC0929 distributed in the selected brain regions
were investigated and showed quite similar distribution patterns
without significant regional differences (Fig. 6). In blocking
studies, the uptake of [11C]HCC0929 in different regions of mice
brain was significantly decreased by co-injection of HCC0929. In
high dose injection (2.88 mg/kg), all the selected brain regions
of mice were decreased significantly as the same; while pretreated
a low dose of HCC0929 (0.288 mg/kg), the cortex, striatum and
hippocampus showed a moderate decrease compared to other mice
brain regions, which were mainly because of the different express
of σ1R in these regions.

The distribution of major organs in mice was analyzed using the
PBAS module in PMOD 4.003. The mean radioactive uptake in
brain and major organs at each time point is showed in Fig. 7. The
highest uptake occurred at 5 min in brain (7.66±0.82% ID/cc), heart (5.10±0.68% ID/cc), lung (6.75±0.86% ID/cc) and kidney (8.87±1.16% ID/cc), and then the radioligand was gradually
washed out from these organs. Whereas in liver and spleen, due to
the accumulation of [11C]HCC0929, the time point of maximum

![Figure 6](image1)

**Figure 6** Time-activity curve demonstrating uptake of radioligand [11C]HCC0929 for baseline and blocking studies (self-blocking, low
blocking dose: 0.288 mg/kg, high blocking dose: 2.88 mg/kg) of different brain regions of mice brain, including cortex, cerebellum, brain stem,
thalamus, hypothalamus, striatum, hippocampus, amygdala.

![Figure 7](image2)

**Figure 7** Biodistribution of radioligand [11C]HCC0929 in rats at 5, 15, 30, and 60 min after injection of radioligand (n = 3 for each time point).
Error bars represent SEM.
uptake was behind other organs. The uptake in liver peaked at 30 min at 14.70±2.03% ID/cc and slightly decreased in 60 min; in spleen, the maximum radioactivity uptake reached in 15 min at 13.32±2.03% ID/cc and then was slowly washed out during study.

3. Conclusions

In summary, two novel carbon-11 labeled $\sigma_R$ radioligands with a 6-hydroxyypyridazinone scaffold, $^{[11]}$C$\text{HCC0923}$ and $^{[11]}$C$\text{HCC0929}$, were successfully prepared and evaluated in mice. Both two radioligands can highly bind to $\sigma_R$ in the mice brain, with good selectivity and specificity. Of the two novel $^{11}$C-labeled sigma-1 receptor radioligands, $^{[11]}$C$\text{HCC0929}$ possessed better kinetic property and specificity which was further investigated in positive ligands blocking studies in mice PET-CT brain imaging, using classic $\sigma_R$ agonist SA 4503 and $\sigma_R$ antagonist PD 144418. Both $\sigma_R$ ligands could extensively decreased the uptake of $^{[11]}$C$\text{HCC0929}$ in mice brain, with different kinetic uptake and washout properties. Besides, the biodistribution of major brain regions and organs of mice were determined in vivo. The radioligand $^{[11]}$C$\text{HCC0929}$ distributed in the selected brain regions showed quite similar distribution patterns as reported, and the distribution in major organs extent the good pharmacokinetic properties in vivo. These results demonstrated its promise as preclinical tools for visualizing and quantitating $\sigma_R$ density in the mice brain in vivo.

Application $^{[11]}$C$\text{HCC0929}$ as PET probes could be used to quantify $\sigma_R$ expression in various neurological disorders, and would also be valuable for evaluation of potential drugs in living subjects. The approach is also valuable for expanding the variety and diversity of PET radiotracers for $\sigma_R$ imaging to meet the requirements for practical clinical application and therefore warrants further investigation.

4. Experimental

4.1. General methods and materials

All commercially available chemical reagents and solvents were of ACS-grade purity or higher, and used without further purification. $^1$H NMR and $^{13}$C NMR spectra data were recorded on a JEOL JNM-ECZ500R Spectrometer (JEOL Ltd, Tokyo, Japan) at 500 MHz ($^1$H) and 126 MHz ($^{13}$C) using chloroform-d. Chemical shifts were given in $\delta$ values (ppm), using tetramethylsilane (TMS) as the internal standard; coupling constants ($J$) were given in Hz. Signal multiplicities were characterized as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad signal).

Analytical thin layer chromatography (TLC) was performed on silica gel GF254. Column chromatographic purification was carried out using silica gel. Analytical separation was conducted on an Agilent 1100 series HPLC (Agilent Technologies, Inc., Santa Clara, CA, USA) fitted with a diode-array detector, quaternary pump, vacuum degasser, and autosampler. Mass spectrometry data were recorded on an Agilent 6310 ion trap mass spectrometer (ESI source, Agilent Technologies, Inc., Santa Clara, CA, USA) connected to an Agilent 1200 series HPLC with quaternary pump, vacuum degasser, diode-array detector, and autosampler.

$^{[11]}$C$\text{CO}_2$ (1.2 Ci) was obtained via the $^{14}$N(p, a)$^{11}$C reaction on nitrogen with 2.5% oxygen, with 11 MeV protons (Siemens Eclipse cyclotron, Siemens Healthcare GmbH, Erlangen, Germany), and trapped on molecular sieves in a TRACERlab FX-Me1 synthesizer (General Electric, GE Healthcare, Boston, MA, USA). $^{[11]}$C$\text{CH}_4$ was obtained by the reduction of $^{[11]}$C$\text{CO}_2$ in the presence of Ni/hydrogen at 350 °C and recirculated through an oven containing $I_2$ to produce $^{[11]}$C$\text{CH}_4$ via a radical reaction.

All animal studies were carried out at Massachusetts General Hospital (MGH, PHS Assurance of Compliance No. A3596-01). The Subcommittee on Research Animal Care (SRAC) serves as the Institutional Animal Care and Use Committee (IACUC) for the Massachusetts General Hospital. SRAC reviewed and approved all procedures detailed in this paper.

Micro PET-CT imaging was performed in anesthetized (iso-flurane) mice (BALB/c) to minimize discomfort. Highly trained animal technicians monitored animal safety throughout all procedures, and veterinary staff were responsible for daily care. All mice were socially housed in cages appropriate for the physical and behavioral health of the individual animal and were given unlimited access to food and water, with additional nutritional supplements provided as prescribed by the attending veterinary staff.

4.2. Chemical synthesis

4.2.1. General procedure for the preparation of intermediates 9 and 10

6-Hydroxy-2-(4-methoxyphenyl)pyrazidin-3(2H)-one (9). To a mixture of (4-methoxyphenyl)hydrazine hydrochloride (7.55 mmol) and maleic anhydride (50 mmol) in $H_2O$ (400 mL), concentrated hydrochloric acid solution (40 mL) was added slowly with stirring. The mixture was heated at 120 °C for 8 h. The progress of the reaction was monitored by TLC. After cooling to room temperature and filtrating, the resulting solid was washed with ice-water and dissolved in a saturated sodium bicarbonate solution. After another filtration, the resulting filtrate was neutralized with 1 mol/L hydrochloric acid and formed a precipitate. The precipitate was then filtered and washed with water to yield 6-hydroxy-2-(4-methoxyphenyl)pyrazidin-3(2H)-one (9), as a white solid (7.22 g, 66.2%). $^1$H NMR (500 MHz, chloroform-d) $\delta$ 7.49 (d, $J=8.7$ Hz, 2H), 7.10–7.02 (m, 2H), 7.00–6.94 (m, 2H), 3.84 (s, 3H). A signal for the OH-proton is not visible. LC–MS Calcd. for C$_10$H$_6$Cl$_2$N$_2$O$_2$ expected [M+H]$^+$: 219.1; Found [M+H]$^+$: 219.1.

2-(3,4-Dichlorophenyl)-6-hydroxyypyrazidin-3(2H)-one (10). The procedure described for the synthesis of 9 was applied to the initial compound 8 (55 mmol), maleic anhydride (50 mmol), and $H_2O$ (400 mL) with concentrated HCl solution (40 mL) to afford 2-(3,4-dichlorophenyl)-6-hydroxyypyrazidin-3(2H)-one (10) as a white solid (9.01 g, 70.1%). $^1$H NMR (500 MHz, chloroform-d) $\delta$ 7.89 (d, $J=8.7$ Hz, 2H), 7.52 (d, $J=8.8$ Hz, 1H), 7.01 (s, 2H). A signal for the OH-proton is not visible. LC–MS Calcd. for C$_{11}$H$_9$I$_6$N$_2$O$_2$ expected [M+H]$^+$: 258.1; Found [M+H]$^+$: 258.1.

4.2.2. General procedure for the preparation of intermediates 11 and 12

6-(3-Bromopropoxy)-2-(4-methoxyphenyl)pyrazidin-3(2H)-one (11). To a solution of 9 (10 mmol) and 1,3-dibromopropane (20 mmol) in acetone (100 mL), potassium carbonate (20 mmol) was added and the mixture was refluxed for 4 h. The progress of the reaction was monitored by TLC. After cooled to room temperature, the mixture was filtered and the solvent was evaporated under reduced pressure. The crude product was purified by means
of flash chromatography (hexane/ethyl acetate = 50/1) to yield 6-(3-bromopropanoyl)-2-(4-methoxyphenyl)pyridazin-3(2H)-one, 11, as a pale-yellow oil (1.89 g, 55.6%). \(^1\)H NMR (500 MHz, chloroform-d) δ 7.57 (d, J = 8.8 Hz, 2H), 7.06–7.01 (m, 2H), 7.00–6.95 (m, 2H), 4.31 (t, J = 5.9 Hz, 2H), 3.84 (s, 3H), 3.55 (t, J = 6.4 Hz, 2H), 2.30 (p, J = 6.2 Hz, 2H). \(^1^3\)C NMR (126 MHz, chloroform-d) δ 158.89, 152.50, 140.63, 134.34, 132.58, 131.48, 130.23, 127.23, 127.60, 124.09, 65.01, 31.62, 29.47. LC–MS Calcd. for \(\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}_3\) as a light yellow oil (1.60 g, 80.6%). \(^1\)H NMR (500 MHz, chloroform-d) δ 7.87 (d, J = 2.4 Hz, 1H), 7.64 (dd, J = 8.7, 2.4 Hz, 1H), 7.50 (d, J = 8.7 Hz, 1H), 6.99 (s, 2H), 4.22 (t, J = 6.4 Hz, 2H), 2.62–2.40 (m, 10H), 2.31 (s, 3H), 1.96 (p, J = 6.7 Hz, 2H). \(^1^3\)C NMR (126 MHz, chloroform-d) δ 158.57, 154.80, 153.03, 140.72, 132.53, 131.38, 130.18, 127.49, 126.72, 124.13, 65.88, 55.11, 1212 Yu Lan et al.

**4.2.3. General procedure for the preparation of compounds 13 to 15**

2-(4-Methoxyphenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (13). A mixture of intermediate 11 (5 mmol) and piperidine (5.5 mmol) in acetonitrile (50 mL) and cesium carbonate (10 mmol) was heated and refluxed for 2 h. After filtering, the resulting filtrate was evaporated to dryness under reduced pressure. The residue was suspended in water (50 mL) and extracted with dichloromethane (3 × 25 mL). The combined organic layers were dried with anhydrous magnesium sulfate, the filtrate was evaporated under reduced pressure, and the crude product was purified by means of flash chromatography (\(\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH} = 10/1\)) to yield \(\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH} = 10/1\) to yield 2-(4-hydroxyphenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (16, precursor P1) as a pale yellow oil (0.142 g, 43.2%). \(^1\)H NMR (500 MHz, chloroform-d) δ 7.32 (d, J = 8.5 Hz, 2H), 7.00–6.91 (m, 2H), 6.84–6.73 (m, 2H), 4.17 (t, J = 6.2 Hz, 2H), 3.00–2.44 (m, 6H), 2.08 (t, J = 7.5 Hz, 2H), 1.82–1.66 (m, 4H), 1.59–1.41 (m, 2H). A weak signal for the \(\text{Ar}–\text{OH}\) proton is δ 8.04, hardly visible. \(^1^3\)C NMR (126 MHz, chloroform-d) δ 159.19, 156.92, 152.77, 133.59, 133.39, 126.89, 126.53, 115.74, 65.32, 55.57, 54.22, 25.02, 24.61, 23.52. LC–MS Calcd. for \(\text{C}_{19}\text{H}_{22}\text{Cl}_2\text{N}_2\text{O}_2\) [\(\text{M} + \text{H}\)^+] as a yellow oil (0.353 g, 397.1190). Found [\(\text{M} + \text{H}\)^+]: 397.2. HR-MS Calcd. for \(\text{C}_{19}\text{H}_{22}\text{Cl}_2\text{N}_2\text{O}_2\) [\(\text{M} + \text{H}\)^+]: 397.1193; Found [\(\text{M} + \text{H}\)^+]: 397.1190.

2-(3,4-Dichlorophenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (17, precursor P2) Under N₂, a solution of 13 (1 mmol) in dichloromethane (14 mL) was kept in an acetone-dry ice bath at −78 °C. 6 mL of Boron tribromide solution (1.0 mol/L in dichloromethane) was added carefully to the stirring solution and kept at −78 °C for 2 h. As the solution of boron tribromide was added, a pale yellow precipitate formed. The reaction mixture was gradually warmed to room temperature and kept stirring overnight. The reaction mixture was then hydrolyzed by careful shaking with 40 mL of H₂O, thus precipitating a white solid, which was dissolved by the addition of 30 mL of dichloromethane. The organic layer was separated and extracted with 20 mL of 2 mol/L sodium hydroxide; the alkaline extract was neutralized with dilute hydrochloric acid and extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried with anhydrous magnesium sulfate, the filtrate was evaporated under reduced pressure, and the crude product was purified by means of flash chromatography (\(\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH} = 10/1\)) to yield 2-(3,4-dichlorophenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (15). The procedure described for the synthesis of 13 was applied to intermediate 12 (5 mmol), 1-methylpiperazine (5.5 mmol), and cesium carbonate (10 mmol) in acetonitrile (50 mL) to afford 2-(3,4-dichlorophenyl)-6-(3-(methylpiperazin-1-yl)propoxy)pyridazin-3(2H)-one, 15 as a light yellow oil (1.60 g, 80.6%). \(^1\)H NMR (500 MHz, chloroform-d) δ 7.87 (d, J = 2.4 Hz, 1H), 7.64 (dd, J = 8.7, 2.4 Hz, 1H), 7.50 (d, J = 8.7 Hz, 1H), 6.99 (s, 2H), 4.22 (t, J = 6.4 Hz, 2H), 2.62–2.40 (m, 10H), 2.31 (s, 3H), 1.96 (p, J = 6.7 Hz, 2H). \(^1^3\)C NMR (126 MHz, chloroform-d) δ 158.57, 154.80, 153.03, 140.72, 132.53, 131.38, 130.18, 127.49, 126.72, 124.13, 65.88, 55.11, 1212 Yu Lan et al.
Novel radioligands for imaging $\sigma_1$R in brain using PET

92.1%). $^1$H NMR (500 MHz, chloroform-$d$) $\delta$ 7.86 (d, $J = 2.4$ Hz, 1H), 7.63 (dd, $J = 8.8$, 2.4 Hz, 1H), 7.51 (d, $J = 8.7$ Hz, 1H), 7.03–6.95 (m, 2H), 4.22 (t, $J = 6.4$ Hz, 2H), 3.25–3.16 (m, 2H), 3.09–2.40 (m, 9H), 2.09–1.89 (m, 2H). $^{13}$C NMR (126 MHz, chloroform-$d$) $\delta$ 158.54, 152.93, 134.27, 134.19, 130.24, 130.20, 127.42, 127.34, 126.72, 124.14, 65.31, 54.58, 50.08, 43.80, 25.88. LC–MS Calcd. for $C_{17}H_{20}Cl_2N_4O_2$ expected $[M+H]^+$: 383.1; Found $[M+H]^+$: 383.1; HR-MS Calcd. for $C_{17}H_{20}Cl_2N_4O_2$ expected $[M+H]^+$: 383.1036; Found $[M+H]^+$: 383.1032.

4.3. Radiosynthesis

$^{11}$C[JHCC0923, $^{11}$C][methyl iodide ($^{11}$C[CH$_3$I) was trapped in a TRACERlab FX-M synthesizer reactor (General Electric) preloaded with a solution of precursor P1 in anhydrous DMF (2.0 mg/mL, 0.3 mL) and NaOH (8 mg). The solution was stirred at 120 °C for 3 min, and 0.1% trifluoroacetic acid (TFA) in water (1.2 mL) was added. The reaction mixture was purified by reverse phase semipreparative HPLC (Agilent Eclipse XDB-C18, 5 μm, 250 mm × 9.4 mm, flow rate = 5.0 mL/min, mobile phase = 0.1% TFA in water/0.1% TFA in acetonitrile, 82/18, v/v), and the desired fraction was collected. The final product was reformulated by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H$_2$O (5 mL), eluting with DMSO (1 mL), and diluting

4.5. Mice PET-CT acquisition and post processing

Male Balb/c mice were tested in groups, each group contained 4 mice, anesthetized with inhalational isoflurane (Patterson Vet Supply, Inc., Greeley, CO, USA) at 2% in a carrier of 2 L/min medical oxygen, and maintained at 1% isoflurane for the duration of the scan.

The mice were arranged side-by-side in two layers in a Triumph Trinome PET/CT/SPECT scanner (Gamma Medica, Northridge, CA, USA). Mice were injected standard references or vehicle via a lateral tail vein catheterization at the start of PET acquisition. Dynamic PET acquisition lasted for 60 min followed by computed tomography (CT) for anatomic coregistration. PET data were reconstructed using a 3D-MLEM method resulting in a full width at half-maximum resolution of 1 mm. Reconstructed images were exported from the scanner in DICOM format along with an anatomic CT for rodent studies. These files were imported and analyzed using AMIDE (a medical imaging data examiner) software (an open-source software, Los Angeles, CA, USA) and PMOD (PMOD4.003, PMOD Technologies Ltd., Zurich, Switzerland).

4.6. Mice PET-CT image analysis

Volumes of interest (VOIs) were generated manually in forms of spheres under the guide of high-resolution CT structural images and summed PET data in mice brain regions, with a radius no less than 1 mm to minimize partial volume effects. Time-activity curves (TACs) were exported as decay-corrected activity per unit volume. The TACs were expressed as percent injected dose per unit volume for analysis.

Acknowledgments

This work was supported by a pilot funding from the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (Changning Wang, USA), National Natural Science Foundation of China (Grant No.81602946, Yu Lan) and Natural Science Foundation of Hubei Province of China (Grant No. 2016CFB258, Yu Lan). The authors are grateful to Prof. Andrew C. Kruse in Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School for the constructive discussion and enthusiastic help in molecular docking, the Athinoula A. Martinos Center Radiopharmacy Lab staff for assistant in radiochemistry and Prof. Xudong Cao in Xuzhou Medical School for the discussion in chemistry and structure identification.
Appendix A. Supporting information

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2019.07.002.

References

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517–32.

2. Zukin SR, Brady KT, Sliker BL, Balster RL. Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors. Brain Res 1984;294:174–7.

3. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of Guinea pig brain. Brain Res 1990;527:244–53.

4. Su TP, Su TC, Nakamura Y, Tsai SY. The sigma-1 receptor as a pluripotent modulator in living systems. Trends Pharmacol Sci 2016;37:262–78.

5. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A 1996;93:8072–7.

6. Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC. Identification of the gene that codes for the δ2 receptor. Proc Natl Acad Sci U S A 2017;114:7160–5.

7. Pabba M. The essential roles of protein–protein interaction in sigma-1 receptor functions. Front Cell Neurosci 2005;7:50.

8. Hayashi T, Su TP. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci U S A 2001;98:491–6.

9. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER–mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007;131:596–610.

10. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009;124:195–206.

11. Van Waarde A, Rybczynska AA, Ramakrishnan N, Ishiwata K, Elsinga PH, Dierckx RA. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharmaceut Des 2010;16:3519–37.

12. Tesei A, Cortesi M, Zamagni A, Arienti C, Pignatta S, Zanoni M, et al. Sigma receptors as endoplasmic reticulum stress “gatekeepers” and their modulators as emerging new weapons in the fight against cancer. Front Pharmacol 2018;9:711.

13. Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Crystal structure of the human δ1 receptor. Nature 2016;532:527–30.

14. Schmidt HR, Betz RM, Dror RO, Kruse AC. Structural basis for δ1 receptor ligand recognition. Nat Struct Mol Biol 2018;25:981–7.

15. Brust P, Deuffer-Conrad W, Lehmkuhl K, Jia H, Wünsch B. Molecular imaging of δ1 receptors in vivo: current status and perspectives. Curr Med Chem 2014;21:35–69.

16. Weber F, Brust P, Laurini E, Prlic S, Wünsch B. Fluorinated PET tracers for molecular imaging of δ1 receptors in the central nervous system. In: Smith SB, Su TP, editors. Sigma receptors: their role in disease and as therapeutic targets. Cham: Springer; 2017. p. 31–48.

17. Jia H, Zhang Y, Huang Y. Imaging sigma receptors in the brain: new opportunities for diagnosis of Alzheimer’s disease and therapeutic development. Neurosci Lett 2019;691:3–10.

18. Toyohara J, Sakata M, Ishiwata K. PET imaging of sigma receptors. In: Dierckx RA, Otte A, De Vries EF, Van Waarde A, Luiten PG, editors. PET and SPECT of neurobiological systems. Berlin, Heidelberg: Springer; 2014. p. 741–63.

19. Kawamura K, Ishiwata K, Tajima H, Ishii SI, Matsuno K, Homma Y, et al. In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors. Nucl Med Biol 2000;27:255–61.

20. Shen B, James ML, Andrews L, Lau C, Chen S, Palner M, et al. Further validation to support clinical translation of [18F]FTC-146 for imaging sigma-1 receptors. JNMNI Res 2015;5:49.

21. Kawamura K, Tsukada H, Shiba K, Tsuji C, Harada N, Kimura Y, et al. Synthesis and evaluation of fluoroine-18-labeled SA4503 as a selective sigma1 receptor radioligand for positron emission tomography. Nucl Med Biol 2007;34:571–7.

22. Waterhouse RN, Collier TL. In vivo evaluation of [18F]-[3-fluoropropyl]-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET. Nucl Med Biol 1997;24:127–34.

23. Waterhouse RN, Zhao J, Stabin MG, Ng H, Schindler-Horvat J, Chang RC, et al. Preclinical acute toxicity studies and dosimetry estimates of the novel sigma-1 receptor radiotracer, [18F]SFE. Mol Imaging Biol 2006;8:284–91.

24. Waterhouse RN, Chang RC, Zhao J, Carambot PE. In vivo evaluation in rats of [18F]-[2-fluoropropyl]-4-(4-cyanophenoxymethyl)piperidine as a potential radiotracer for PET assessment of CNS sigma-1 receptors. Nucl Med Biol 2006;33:211–5.

25. James ML, Shen B, Zavala CL, Nielsen CH, Mesangeau C, Vuppala PK, et al. New positron emission tomography (PET) radioligand for imaging σ1 receptors in living subjects. J Med Chem 2012;55:8272–82.

26. Hjornevik T, Cipriano PW, Shen B, Park JH, Gulaka P, Holley D, et al. Biodistribution and radiation dosimetry of [18F]-FTC-146 in humans. J Nucl Med 2017;58:2004–9.

27. NIH-U.S. National Library of Medicine, ClinicalTrials. gov, Identifier: NCT02753101. Available from: https://clinicaltrials.gov/ct2/show/NCT02753101?term=FTC-146&rank=1#searchwrapper.

28. Cao X, Chen Y, Zhang Y, Lan Y, Zhang J, Xu X, et al. Synthesis and biological evaluation of novel σ1 receptor ligands for treating neuropathic pain: 6-hydroxypyridazinones. J Med Chem 2016;59:2942–61.

29. Lan Y, Chen Y, Cao X, Zhang J, Wang J, Xu X, et al. Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain. J Med Chem 2014;57:10404–23.

30. McOmie JF, West DE. 3,3′-dihydroxydiphenyl. Org Synth 1969;49:50–2.

31. Van De Bittner GC, Ricq EL, Hooker JM. A philosophy for CNS radiotracer design. Acc Chem Res 2014;47:3127–34.

32. Weissman AD, Su TP, Hedreen JC, London ED. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 1988;247:29–33.

33. Kohnhuber J, Schoppmeyer K, Bending C, Riederer P. Characterization of [1H]Pentazocine binding sites in post-mortem human frontal cortex. J Neural Transm (Vienna) 1996;103:45–53.

34. André S, Rosés M, Ráfols C, Bosch E, Espinosa S, Segarra V, et al. Setup and validation of shake-flask procedures for the determination of partition coefficients (log D) from low drug amounts. Eur J Pharm Sci 2015;67:181–91.

35. Linkens K, Schmidt HR, Sahn JJ, Kruse AC, Martin SF. Isoliningoidine, tetrahydrodiosquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties. Eur J Med Chem 2018;151:557–67.

36. Wang C, Schroeder FA, Hooker JM. Development of new positron emission tomography radiotracer for BET imaging. ACS Chem Neurosci 2017;8:17–21.

37. Wang C, Schroeder FA, Wey HY, Borra R, Wagner FF, Reis S, et al. In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. J Med Chem 2014;57:7999–8009.

38. Mu Y, Hof PR, Grant SC, Blackband SJ, Bennett R, Stalset L, et al. A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience 2005;135:1203–15.

39. Mirrione MM, Schiffer WK, Fowler JS, Alexoff DL, Dewey SL, Tsirka SE. A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures.
in the absence of tissue plasminogen activator. Neurorimage 2007;38:34–42.

40. Kawamura K, Kobayashi T, Matsuno K, Ishiwata K. Different brain kinetics of two sigma receptor ligands, \( [\text{H}]^{(+)} \)-pentazocine and \( [\text{C}]^{(1)} \)SA4503, by P-glycoprotein modulation. Synapse 2003;48:80–6.

41. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177–96.

42. Akunne HC, Whetzel SZ, Wiley JN, Corbin AE, Ninteman FW, Tecle H, et al. The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology 1997;36:51–62.

43. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2:131–7.